ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements with these filters
Astec LifeSciences responded to an NSE surveillance query on volume spurt. The company confirmed no developments requiring mandatory disclosure under LODR or PIT Regulations.
Astec LifeSciences Limited has confirmed the timely payment of the maturity amount for its commercial paper. The redemption amount totals ₹25 Crore.
Astec LifeSciences replied to an NSE volume-spike surveillance notice, confirming full disclosure compliance. No undisclosed developments exist under Listing or PIT Regulations.
Astec LifeSciences has set record dates for the redemption of three Commercial Paper series, with each series maturing at a value of ₹25 Crore.
Astec LifeSciences held its 32nd AGM on July 31, 2026. The meeting approved financial statements, director re-appointment, and cost auditor remuneration.
Astec LifeSciences announced its Q1 FY27 financial results, reporting total income of ₹84.3 crore and an EBITDA of ₹0.1 crore.
Astec LifeSciences confirmed nil deviation in the utilization of proceeds from its listed Non-Convertible Debentures for the quarter ended 30th June, 2026.
Astec Lifesciences Ltd reported revenue from operations of ₹83.6 Cr (-8.2% YoY) and a net loss of ₹18.7 Cr for Q1 FY27.
Astec LifeSciences Ltd scheduled a board meeting on July 31, 2026, to approve unaudited financial results for the quarter ended June 30, 2026.
Astec Lifesciences Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing lists promoters and public shareholders' stakes.
Astec LifeSciences scheduled its AGM for July 31, 2026. Agenda includes financial statement adoption, director re-appointment, and ratifying auditor remuneration of Rs. 0.015 Crore.
Astec LifeSciences submitted its FY 2025-26 Annual Report and AGM notice. The 32nd Annual General Meeting is scheduled for July 31, 2026.